11 Mar, 2016Top 8 Innovation Picks for February 2016


Let’s keep the conversation going — use hashtag #sparkofinnovation to join the conversation on Twitter and Facebook!

Read More

01 Oct, 2013Patient-Reported Outcomes In Cancer Management – Part 2


A personalized medicine approach to clinical cancer therapy does not necessarily translate into a patient-centered approach as discussed in part 1 of this…

Read More

02 Apr, 2013Drug Discovery in Snake Venom


The black mamba’s venom is so potent that one bite spells almost certain death, in the absence of antivenom. At least the snake…

Read More

22 Jan, 2013Rare Diseases: Orphans No Longer


One welcome result of the pharmaceutical innovation crisis is a shift from blockbuster drugs to rare disease drugs. We are doing our own…

Read More

14 May, 2012Buying Innovation: A Look at Pharmaceutical Mergers and Acquisitions


We’ve looked at what happens to a drug when a patent expires, but what happens to the patent owner? As patents have expired and many blockbuster drugs become generic, pharmaceutical companies have looked to new drugs and innovations to replace the lost income. Getting a drug through regulatory hurdles, such as clinical trials and safety testing, is difficult and millions of dollars can be lost from an unexpected failure. As many patents have expired and only a few drugs have replaced them in the past decade, pharmaceutical companies have looked to mergers and acquisitions for new products and drugs in an effort to buy innovation.

Read More

05 Mar, 2012Access Granted: What Happens When the Patent Expires?


The price of pharmaceutical drugs has been an issue of national debate for decades. As many blockbuster drugs face patent expiration in a…

Read More